Use of COVID-19 Vaccines and Therapeutics with Long-Acting Cabotegravir and Rilpivirine

Summary

- No drug interaction studies between long-acting cabotegravir and rilpivirine (CAB + RPV LA) and any COVID-19 vaccines and therapeutics have been conducted.
- Use of dexamethasone with CAB + RPV LA is contraindicated.
  - Consult local and international guidelines for alternatives to dexamethasone.
- Important Safety Information and Boxed Warning can be found in the Prescribing Information and can also be accessed from the Our HIV Medicines section of viivhealthcare.com/us.

To access additional scientific information related to ViiV Healthcare medicines, visit the ViiV US Medical Portal at viivhcmedinfo.com.

No drug interaction studies have been conducted with CAB + RPV LA and any COVID-19 vaccines and therapeutics. Since the pathways of metabolism and elimination are independent of formulation type, the data from oral CAB and oral RPV have been extrapolated to identify drugs with which use of CAB + RPV LA may cause an interaction.[1-8]

COVID-19 VACCINES AND THERAPEUTICS

No drug interaction studies between CAB and RPV and any COVID-19 vaccines and therapeutics have been conducted. Except for dexamethasone (see below), there are no specific recommendations on the use of any SARS-CoV-2 vaccines and therapeutics with CAB + RPV LA.[9] However, based on the pharmacological profile of CAB + RPV LA and the vaccines and therapeutics listed below (except dexamethasone), no drug interactions are anticipated.

Vaccines[10]

Adenoviral vector vaccines – Janssen COVID-19 vaccine, Oxford/Astra Zeneca COVID-19 vaccine

Messenger RNA (mRNA) vaccines – Moderna COVID-19 vaccine, Pfizer-BioNTech COVID-19 vaccine

Adjuvanted recombinant protein vaccines – Novavax COVID-19 vaccine, Sanofi-GSK COVID-19 vaccine

Therapeutics[11-13]

Dexamethasone

Dexamethasone is a dose-dependent inducer of cytochrome CYP 3A4.[14] Because rilpivirine is a substrate of CYP 3A4 a reduction in the plasma concentrations of rilpivirine is expected.[9] As such, use of dexamethasone (>1 dose) with rilpivirine is contraindicated.

Consult local and international guidelines, such as those published by the World Health Organization, the US National Institutes of Health, and the Infectious Diseases Society of America for possible alternatives to dexamethasone.[11-13]

PaxlovidTM (nirmatrelvir tablets; ritonavir tablets)

While specific data with CAB + RPV LA are unavailable, a significant drug-drug interaction is unlikely. Both components (nirmatrelvir and ritonavir) are CYP3A substrates and both inhibit CYP3A; CAB is not a clinically relevant inhibitor or inducer of CYP3A4, thus no interaction with CAB is expected.[15] Drug interaction data for oral RPV with ritonavir-boosted therapies have shown that rilpivirine concentrations may increase; however, these can be coadministered without any dosage adjustments.[16]

Remdesivir

Molnupiravir

Baricitinib

SARS-CoV-2 monoclonal antibodies

- Casirivimab and Imdevimab - Casirivimab and imdevimab are monoclonal antibodies which are not renally excreted or metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are renally excreted or that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.[17]
- Bamlanivimab and Etesevimab - Bamlanivimab and etesevimab are not renally excreted or metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are renally excreted or that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.[18]
- Tixegevimab and Cilgavimab - Drug-drug interaction studies have not been performed. Based on key elimination pathways, tixagevimab and cilgavimab interactions with concomitant medications that are renally excreted or that are substrates, inducers, or inhibitors of CYP enzymes are unlikely.[19]

Interleukin-6 inhibitors – tocilizumab, sarilumab, siltuximab

Anakinra

Interferons (alfa, beta)

Additional Information

For inquires on interactions with other drugs that are not listed here it is recommended to consult a reputable drug interaction website such as https://www.covid19-druginteractions.org/checker and https://www.hiv-druginteractions.org/checker.

Some information contained in this response may not be included in the approved Prescribing information. This response is not intended to offer recommendations for administering this product in a manner inconsistent with its approved labeling. Please note that reports of adverse events in the published literature often lack causality assessments and may contain incomplete information; therefore, conclusions about causality generally cannot be drawn.

In order for ViiV Healthcare to monitor the safety of our products, we encourage healthcare professionals to report adverse events or suspected overdoses to the company at 877–844–8872. Please consult the attached Prescribing Information.

This response was developed according to the principles of evidence-based medicine and, therefore, references may not be all-inclusive.

REFERENCES

1. Bowers GD, Culp A, Reese MJ, et al. Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. *Xenobiotica*. 2016;46(2):147-162. doi:http://dx.doi.org/10.3109/00498254.2015.1060372.
2. Ford SL, Gould E, Chen S, et al. Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744. *Antimicrobial agents and chemotherapy*. 2013;57(1):277-280. doi:http://dx.doi.org/10.1128/AAC.01685-12.
3. Reese MJ, Bowers GD, Humphreys JE, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. *Xenobiotica*. 2016;46(5):445-456. doi:http://dx.doi.org/10.3109/00498254.2015.1081993.
4. Trezza C, Ford SL, Spreen W, Pan R, Piscitelli S. Formulation and pharmacology of long-acting cabotegravir. *Curr Opin HIV AIDS*. 2015;10(4):239-245. doi:http://dx.doi.org/10.1097/coh.0000000000000168.
5. Trezza C, Ford SL, Gould E, et al. Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. *Br J Clin Pharmacol*. 2017;83(7):1499-1505. doi:http://dx.doi.org/10.1111/bcp.13236.
6. Blair CS LS, Chau G, et al. Blair CS, Li S, Chau G, et al. Hormonal Contraceptives Do Not Alter Cabotegravir PK in HIV Uninfected Women. Presented at CROI 2019; March 4-7, 2019; Seattle, WA. Poster 1791.
7. Ford SL, Sutton K, Lou Y, et al. Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects. *Antimicrob Agents Chemother*. 2017;61(10). doi:http://dx.doi.org/10.1128/aac.00487-17.
8. Ford SL, Lou Y, Lewis N, et al. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects. *Antivir Ther*. 2019. doi:http://dx.doi.org/10.3851/imp3306.
9. Local label(s).
10. Forni G, Mantovani A, Covid-19 Commission of Accademia Nazionale dei Lincei R. COVID-19 vaccines: where we stand and challenges ahead. *Cell Death Differ*. 2021;28(2):626-639. doi:http://dx.doi.org/10.1038/s41418-020-00720-9.
11. World Health Organization. Corticosteroids for COVID-19 - Living Guidance. Published on September 2, 2020. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1. Accessed on February 26. 2021.
12. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed February 24, 2021.
13. Bhimraj A, Morgan RL, Hirsch Shumaker A, et al. IDSA Guidelines on the treatment and management of patients with COVID-19. Available at: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Accessed on February 26, 2021.
14. McCune JS, Hawke RL, LeCluyse EL, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. *Clin Pharmacol Ther*. 2000;68(4):356-366. doi:http://dx.doi.org/10.1067/mcp.2000.110215.
15. Paxlovid Fact Sheet. Pfizer Laboratories 2022. Available at www.labeling.pfizer.com.
16. Prescribing Information for Edurant (rilpivirine) JP. Prescribing Information for Edurant (rilpivirine), Janssen Products. 2011.
17. Fact Sheet for Health Care Providers Emergency Use Authorization of Regen-COV (casirivimab and imdevimab). Available at www.https://www.fda.gov/media/145611/download. Accessed June 13, 2022.
18. Fact Sheet for Health Care Providers Emergency Use Authoriziation of Bamlanivimab and Etesevimab. Available at: https://www.fda.gov/media/145802/download. Accessed June 13, 2022.
19. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Tixegevimab co-package with cilgavimab. Available at www.fda.gov/media/15401. Accessed June 13, 2022.